On Wednesday (January 24) Canaccord Genuity hosted a cannabis investor day, where companies in the space pitched their concepts for the future of the market and how exactly their business could fit into that picture.
In total there were 28 presenting companies, from a mix of TSX listed LPs, TSX Venture opportunities, and companies operating in Canada through the Canadian Securities Exchange (CSE), but with a focus on the US cannabis market. The conference also had presentations from a variety of currently private companies detailing their plans to go public later this year.
The conference began with opening remarks from Canaccord Genuity cannabis analyst Matt Bottomley, who said right now there is an “incredible amount of cash” being deployed into the industry. Despite the volatility and the changes companies in this space face nearly on a daily basis, Bottomley said in his expectation this industry is rooted in the fundamentals that will make it successful.
Bottomley also explained how Canada and the players in this country have a first mover advantage on a worldwide scale. This notion of Canada as a worldwide leader for cannabis was also discussed during the Lift Cannabis Expo in Vancouver.
Bottomley added people are “flooding to Canada” as a recognition of the steps the country has taken to bring the issue of cannabis to the forefront.

Packed room for Aurora presentation on the heels of the CanniMed acquisition

One of the most anticipated presentations was for Aurora Cannabis (TSX:APH; OTCQB:ACBFF) thanks in no part to its recent acquisition of CanniMed Therapeutics (TSX:CMED).
“We’ll never do another hostile takeover again, ever,” Terry Booth CEO of Aurora told the audience. Booth ran over the company’s most recent updates including its export potential in Australia, its plans for the German and Danish markets as well as a recent announcement in Italy. On January 18, Aurora earned an exclusive deal with the Italian Ministry of Defense to supply them with medical cannabis.
One of Aurora’s potential catalysts is the much detailed Aurora Sky facility, an 800,000 square foot high-technology greenhouse facility located near the Edmonton International Airport. Booth said the facility is on budget and on schedule. According to the government of Alberta, the production is expected to produce the first harvest in the second quarter of 2018.
Booth said that thanks to the CanniMed deal, Aurora will be able to use an extra 50,000 square feet for production. He explained the $1.1 billion was worth it to end the transaction in friendly terms, instead of dragging out the issue.
“If we had to take this ugly and continue to march and deal with the Newstrike boys–whom I like–but there’s lots of Newstrike’s out there,” Booth said.


InvestorsUpdate from other companies at the Canaccord Genuity cannabis conference

MedReleaf (TSX:LEAF) took the stage to tell investors about their core focus growth drivers in 2018: the Canadian medical market continued work into innovative products for consumers, the recreational market in Canada and international opportunities for them like Brazil, Germany, and Australia.
One of the most interesting details shared in MedReleaf’s conference was the work being done to complete a cannabis test for patients capable of indicating, through genetics, how high of a dose they need for their particular ailment, depending on their reaction to cannabis.
One of the major prospects for recreational cannabis in Canada this year is the potential cultural shift about the drug and its perception with non-users.
Companies like MedReleaf spoke on the need to provide support and education to physicians so they are more comfortable recommending cannabis medicament to their patients. A test like the one MedReleaf presented could provide the data needed to start changing the mind of medical officials across Canada.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Other efforts, like the one presented by Namaste Technologies (CSE:N; OTC:NXTTF) show the potential of lifestyle apps collecting the data required to create a significant change in this area. Sean Dollinger, president, and CEO of Namaste told the audience the company is launching an Apple Watch app which will be capable of monitoring patients after consuming cannabis.
During its presentation, Delta 9 (TSXV:NINE) outlined its option in the Manitoba market. John Arbuthnot, CEO of Delta 9, told the audience he expected the provincial government there to reveal the winners of the four planned retail licensed next week.
Delta 9 has also extended its partnership with Canopy Growth (TSX:WEED), under the CraftGrow outreach program. If awarded the key license, Delta 9 plans to bring this partnership to their licensed sale of medical and recreational cannabis in Manitoba.
Arbuthnot also took time to explain the company’s unique growing method. Delta 9 employs what they call Delta 9 grow pods, which are shipping containers modified to accommodate the growth of between 30 and 32.5 kilos on an annualized basis. Each pod costs Delta 9 $40,000 to customize and, according to Arbuthnot, presents a key advantage in safety terms.
Since the pods are independently managed they don’t pose a risk, particularly if there were to be a problem with a specific crop. As he explained on the Midas Letter podcast, a heating, ventilating, and air conditioning (HVAC) system runs the risk of an infestation spreading throughout the facility.
“When we compartmentalize our risk, our entire value at risk in any one container at any given time is in the tens of thousands of dollars,” Arbuthnot said.

Investor Takeaway

Despite the current potential for the marijuana business right now, the Canaccord conference dedicated moments remembering how far the industry has come in just a few years. According to data provided by Canaccord, the financial institution has raised $1.5 billion for the cannabis industry since 2016.
There are plenty of opportunities for investors looking into the cannabis space, and not only from the major LPs dominating the headlines. There is exciting innovation coming from players from all sizes through all the public exchanges.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

The potential for new disease research and treatments is expanding thanks to the global adoption of marijuana for medical purposes.

As more countries open the doors to the use and investigation of cannabis, medical applications for the drug are set to expand — indeed, it has already shown much promise.

However, in terms of treating skin cancer patients, currently the promise of cannabis outpaces any medically confirmed results or applications.

Though there may be individual cases claiming to credit the drug, cannabis and its derivatives are not being applied for the treatment of skin cancer. Read on to learn more.

Skin cancer, cannabis and medical research

According to the American Cancer Society, skin cancer is the most common type of cancer, accounting for over 5 million cases per year. This category holds many different variations, but the main three types are basal cell carcinomas, squamous cell carcinomas and melanomas; the rest are considered rare.

Melanomas develop in specific areas like the neck and face and can be more serious than their counterparts. Basal and squamous cancer cells, on the other hand, are developed based on a person’s sun exposure and mostly develop in the head and neck.

The Canadian Cancer Society states that treatments of non-melanoma skin cancer include surgery, radiation therapy, photodynamic therapy and drug therapy, including the use of topicals.

Cannabis and cancer could be paired up as more research across the globe begins to take place, looking for new medications and formulations, boosted by the early successes of the drug.

While research is still lacking in the overall medical marijuana space, there have been serious improvements, such as GW Pharmaceuticals (NASDAQ:GWPH) obtaining approval in the US for its cannabidiol (CBD) solution, which treats seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in toddlers.

After going through its clinical trials, the company’s Epidiolex drug approval from the US Food and Drug Administration, signaling that top medical agencies are ready to confirm the medical prowess of cannabis and its derivatives for the benefit of patients.

Cannabis entering the skincare space

Looking more specifically at cannabis and skin ailments, the National Eczema Association has vouched for CBD as an option in the treatment of eczema, a skin disease that affects over 30 million people in the US.

“It has long been observed that cannabinoids possess anti-inflammatory, antimicrobial and anti-itch qualities,” the Independent reported.

A study from the the University of Colorado School of Medicine is looking further into the use of CBD for patients with psoriasis or eczema who have tried using topical steroids or topical immunomodulators.

Robert Dellavalle, professor of dermatology with the University of Colorado, told Inside Science that CBD products are growing in popularity, but the results are not being collected as properly as it could be.

“I believe it’s a wide-open horizon with tremendous potential that needs to be investigated, but there are a number of regulatory hurdles that need to be overcome and that’s where we are,” he said of his study.

A medical study from the University of Colorado Anschutz Medical Campus shows that the anti-inflammatory sensibilities of cannabinoids are the main reason why they may be a potent agent in combating skin diseases.

As part of its guide for healthcare practitioners, Tilray (NASDAQ:TLRY) indicates that medical cannabis could aid patients with inflammatory skin diseases such as dermatitis, psoriasis and pruritus.

“And while this research is still relatively formative, the results achieved so far clearly indicate its value and the promising potential of cannabis as effective medicine,” Tilray wrote.

Dave Berg, chief technology officer for software company Strainprint, told the Investing News Network the lack of sophisticated research has impacted the development of novel therapies for patients using cannabis.

“It’s been very difficult for people to study cannabis in a clinical way, but there’s been a ton observational data … There’s no really strong observational data set that allows us to make proper decisions,” Berg said.

In an effort to increase the research options available for cannabis, the Canadian federal government announced plans to spend C$10 million over five years in order to assess the impact of cannabis use on the mental health of Canadians.

The government also promised C$10 million to the Canadian Center on Substance Use and Addiction for research purposes.

Skin treatment, either cosmetic or medical, has been one of the many sectors revitalized as new cannabis oil products gain popularity. These cannabis oil products are developed based on the non-psychoactive component of the marijuana plant, CBD.

The introduction of cosmetics with cannabis elements, supported by Canadian licensed producers, is another upcoming element for the skin treatment segment of consumers, and while not medical it does offer more options to the uses of cannabis.

The endorsement from consumers for CBD ointments or other topicals for skincare has been documented with multiple products launched in the fractured US cannabis market.

One downside of the increasing popularity of these products is that it has led companies to make more and more claims about how these items can help with skin conditions. One study from the Journal of the American Medical Association warns that CBD products are often mislabeled online.

Takeaway on cannabis and skin cancer

In order for skin cancer patients to see the potential benefits from treatments with medical cannabis, a lot still has to change in Canada and abroad.

As the medical and recreational sections of the cannabis space continue drifting apart thanks to legalization efforts, the medical space should obtain more time to properly research and investigate the drug’s applications.

The early position CBD has gained in terms of skin maintenance and treatment could lead to further research on its impact with a more serious disease.

What’s more, the given to GW Pharmaceuticals and the increased awareness of the medical benefits for cannabis is moving the needle for how much more research will be put to find out how capable the drug will be in the medical space.

Keep reading... Show less

The growth of the cannabis industry has made it possible for companies to offer investment opportunities through the major listing exchanges in Canada.

Previously known as the Canadian Venture Exchange, the TSX Venture Exchange is the sibling listing to the larger Toronto Stock Exchange.

This listing offers a variety of cannabis-related businesses from growers to biotech companies looking for cannabinoid therapies for those interested in investing in cannabis companies.

Here the Investing News Network offers investors a growing list of all cannabis-related companies listed on the TSXV.

48North (TSXV:NRTH)

This company is a marijuana producer looking to offer a variety of products for the recreational market in Canada, including for the health and wellness industry. The firm is a licensed outdoor grower of cannabis.

Auxly Cannabis Group (TSXV:XLY,OTCQX:CBWTF)

Founded by Chuck Rifici, Tweed co-founder, Auxly operates as a cannabis streaming investment firm looking to boost various plays related to the sector.

Avricore Health (TSXV:AVCR,OTCQB:AVCRF)

While Avricore operates as a healthcare technology company, in 2017 the firm made a deal with Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF) for the right to develop and sell endocannabinoid products in Canada to licensed pharmacies.

CanadaBis Capital (TSXV:CANB)

This cannabis company is targeting the Canadian market through its business model that is focused on cultivation, research, product development, retail and hemp.

Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF)

This Canadian cannabis company holds a variety of growing assets in the country. The firm holds a 50/50 joint venture for the management of a grower in BC with Village Farms International (TSX:VFF,NASDAQ:VFF).

EnWave (TSXV:ENW,OTC Pink:NWVCF)

EnWave is a technology company that has centered itself in the cannabis business thanks to its Radiant Energy Vacuum drying technology for organic materials. It effectively decreases the time from the harvest to the sale of cannabis products.

Elixxer (TSXV:ELXR,OTCQB:ELIXF)

Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada.

Eve & Co. (TSXV:EVE,OTCQX:EEVVF)

Eve & Co. is a Canadian cannabis producer that, thanks to its subsidiary Natural MedCo, is seeking to target women consumers specifically with premier brands.

Experion Holdings (TSXV:EXP,OTCQB:EXPFF)

Formerly known as Viridium Pacific Group, this cannabis investment firm holds a portfolio of assets, including its licensed producer Experion Biotechnologies in Mission, BC.

The Flowr Corporation (TSXV:FLWR,OTC Pink:FLWPF)

Flowr is a vertically integrated cannabis company working on the cultivation and sale of medical and recreational marijuana in Canada.

FluroTech (TSXV:TEST,OTCQB:FLURF)

FluroTech is a technology company working on a cost-effective testing platform for the cannabis industry at large. The company’s proprietary CompleTest employs fluorescence spectroscopy technology to measure the specific contents of the product.

GTEC Holdings (TSXV:GETC,OTCQB:GGTTF)

This Kelowna-based cannabis company is vertically integrated, with operations in the cultivation, extraction and analytical testing sectors. The company is also pursuing retail operations through various investments.

Harvest One Cannabis (TSXV:HVT,OTCQX:HRVOF)

Harvest One is a cannabis company with production and assets spread across Canada, Europe, Israel and Australia. The company gains its reach thanks to its three subsidiaries: United Greeneries, Satipharm and Dream Products.

Hill Street Beverage Company (TSXV:BEER)

This beverage maker has made its name thanks to its development of non-alcoholic beverages. Now, the firm will offer consumers cannabis-infused drinks.

INDIVA (TSXV:NDVA,OTCQX:NDVAF)

INDIVA is a company focused on the supply of medical cannabis. Through an acquisition, this company holds a licensed producer with an indoor cannabis facility in Ontario.

Khiron Life Sciences (TSXV:KHRN,OTCQB:KHRNF)

Khiron is a Colombia-based cannabis company raising capital in Canada through the TSXV. The firm has declared that it will seek to expand its presence through Latin America, including Mexico.

Meta Growth (TSXV:META)

This company is a retail operator managing cannabis shops across the country. National Access Cannabis manages two recreational store brands: Meta Cannabis Supply and NewLeaf Cannabis.

Namaste Technologies (TSXV:N,OTCQB:NXTTF)

After undergoing a tumultuous management change, Namaste has centered back on its investments and development of its marijuana play, which includes its online platform of cannabis consumer information.

Naturally Splendid Enterprises (TSXV:NSP,OTCQB:NSPDF)

Naturally Splendid is a biotech company working on the development of hemp products for consumers in the health and wellness space. The company will pursue a stake in the edible CBD market as well.

Pharmacielo (TSXV:PCLO,OTC Pink:PHCEF)

Pharmacielo is another cannabis company originally from Colombia raising capital in the Canadian markets. The company is headquartered in Canada but operates as part of its marijuana growing in Rionegro, Colombia.

Radient Technologies (TSXV:RTI,OTCQX:RDDTF)

Radient is an extraction technology company that has dabbled in the cannabis sector thanks to a partnership with licensed producer Aurora Cannabis (TSX:ACB,NYSE:ACB).

Relevium Technologies (TSXV:RLV,OTCQB:RLLVF)

Thanks to its subsidiary Biocannabix, this company has a cannabis play in the development of pharmaceutical grade products infused with cannabinoid formulations.

SugarBud Craft Growers (TSXV:SUGR)

Like some other Canadian cannabis producers, this Alberta company specializes in growing and developing craft style premium cannabis products.

Target Capital (TSXV:TCI)

Doing business as CBi2 Capital, this Calgary, Alberta based company’s cannabis focused investment strategy focuses on developing and managing a diversified portfolio of predominantly early stage cannabis investment opportunities.

Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF)

Tetra Bio-Pharma is a company working on the research and development of medicines based on cannabis and its elements.

Therma Bright (TSXV:THRM)

Therma Bright is a medical device company that has a subsidiary seeking to carve up a space in the technology space for medical and recreational marijuana thanks to its pain relief device.

WeedMD (TSXV:WMD,OTCQX:WDDMF)

WeedMD is another Canadian cannabis producer making product for the medical and recreational markets in Canada.

YSS (TSXV:YSS)

YSS operates as an adult-use cannabis retailer with 17 stores in Canada.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less